

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (Currently Amended) A recombinant protein having an anti-cancer effect, which is one selected from the group consisting of:

1) a protein having the amino acid sequence of SEQ ID No:2 shown in the sequence listing;

2) a protein derived from SEQ ID No:2, which has a sequence homology of more than 90% with SEQ ID No:2 and which has the same activity as that of SEQ ID No:2; and

~~3) a protein derived from SEQ ID No:2, which is obtained by adding or deleting 15 or less amino acid residues at the N-terminus of the amino acid sequence of SEQ ID No:2, and which has the same activity as that of SEQ ID No:2;~~

~~4) a protein derived from SEQ ID No:2, which is obtained by adding or deleting 15 or less amino acid residues at the C-terminus of the amino acid sequence of SEQ ID No:2, and which has the same activity as that of SEQ ID No:2;~~

[[5]]3) a protein derived from SEQ ID No:2, which is obtained by substitution, deletion, or addition of one or several amino acid residues in the amino acid sequence of SEQ ID No:2, and which has the same activity as that of SEQ ID No:2.

2. (Currently Amended) The protein according to Claim 1, ~~characterized in that~~ wherein said protein is SEQ ID No:2 shown in the sequence listing.

3. (Currently Amended) A gene encoding a recombinant protein having an anti-cancer effect, which gene is one selected from the group consisting of:

1) SEQ ID No:1 shown in the sequence listing;

2) a polynucleotide encoding the amino acid sequence of SEQ ID No:2 shown in the sequence listing;

3) a DNA sequence which has more than 90% sequence homology with the DNA sequence defined by SEQ ID No:1 shown in the sequence listing and which encodes a protein having the same activity as that of a protein encoded by SEQ ID No:1; and

~~4) a DNA sequence encoding a protein derived from SEQ ID No:2, wherein said protein derived from SEQ ID No:2 is obtained by adding or deleting 15 or less amino acid residues at the N-terminus of the amino acid sequence of SEQ ID No:2, and has the same activity as that of SEQ ID No:2;~~

~~5) a DNA sequence encoding a protein derived from SEQ ID No:2, wherein said protein derived from SEQ ID No:2 is obtained by adding or deleting 15 or less amino acid residues at the C-terminus of the amino acid sequence of SEQ ID No:2, and has the same activity as that of SEQ ID No:2;~~

[[6]]4) a DNA sequence encoding a protein derived from SEQ ID No:2, wherein said protein derived from SEQ ID No:2 is obtained by substitution, deletion, or addition of one or several amino acid residues in the amino acid sequence of SEQ ID No:2, and has the same activity as that of SEQ ID No:2.

4. (Currently Amended) The gene according to Claim 3, ~~characterized in that~~ wherein said gene is SEQ ID No:1 shown in the sequence listing.

5. (Original) A medicament for treating cancers comprising the recombinant protein according to Claim 1 as the active ingredient.

6. (Currently Amended) The medicament according to Claim 5, ~~characterized in that~~ wherein said protein is SEQ ID No:2 shown in the sequence listing.

7. (Currently Amended) ~~The medicament according to Claim 5 or 6, characterized in that said medicament further comprises a pharmaceutically acceptable carrier which is acceptable to a human~~ An expression vector comprising the gene according to Claim 3.

8. (Original) An expression vector comprising the gene according to Claim 4.
9. (Currently Amended) A cell line comprising ~~containing~~ the gene according to Claim 4.
10. (Currently Amended) [~~Use of~~]A method of the preparing a medicament for treating cancers comprising placing the recombinant protein according to Claim 1 in the preparation of a medicament for treating cancers with a pharmaceutically acceptable carrier.
11. (Currently Amended) ~~Use of the recombinant protein according to Claim 2 in the preparation of a medicament for treating cancers~~ A method according to Claim 10 wherein said protein is SEQ ID No:2 shown in the sequence listing.
12. (New) A method according to Claim 10 wherein said cancer is selected from the group consisting of colon cancer, lung cancer, multiple myeloma, brain glioma, leukemia, breast cancer, small-cell lung cancer and pancreas cancer.
13. (New) A method according to Claim 11 wherein said cancer is selected from the group consisting of multiple myeloma, leukemia, brain glioma, lung cancer and colon cancer.
14. (New) A method for treating cancers in a subject, comprising administering to said subject an effective amount of the protein of Claim 1.
15. (New) The method according to Claim 14, wherein said cancer is selected from the group consisting of colon cancer, lung cancer, multiple myeloma, brain glioma, leukemia, breast cancer, small-cell lung cancer, and pancreas cancer.

Applicant : Bing Zhu  
Serial No. : To Be Assigned  
Filed : Herewith  
Page : 6 of 7

Attorney's Docket No.: 20807 002US1 / FPCH06160002US

16. (New) The method according to Claim 15, wherein said protein is SEQ ID No:2 shown in the sequence listing and said cancer is selected from the group consisting of multiple myeloma, leukemia, brain glioma, lung cancer and colon cancer.